SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Simren Magnus)
 

Sökning: WFRF:(Simren Magnus) > Randomized clinical...

Randomized clinical trial: Effects of Aloe barbadensis Mill. extract on symptoms, fecal microbiota and fecal metabolite profiles in patients with irritable bowel syndrome

Ahluwalia, Bani (författare)
Gothenburg University,Göteborgs universitet,Institutionen för biomedicin,Institute of Biomedicine,University of Gothenburg
Magnusson, Maria K, 1972 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för biomedicin,Institute of Biomedicine,University of Gothenburg
Böhn, Lena (författare)
Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine,University of Gothenburg
visa fler...
Störsrud, Stine (författare)
Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine,University of Gothenburg
Larsson, F. (författare)
Savolainen, Otto, 1982 (författare)
Chalmers tekniska högskola,Chalmers University of Technology
Ross, Alastair, 1976 (författare)
Chalmers tekniska högskola,Chalmers University of Technology,AgResearch,AgResearch Lincoln
Simrén, Magnus, 1966 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine,The University of North Carolina System,University of Gothenburg
Öhman, Lena, 1967 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institutionen för biomedicin,Institute of Medicine,Institute of Biomedicine,University of Gothenburg
visa färre...
 (creator_code:org_t)
2020-04-20
2020
Engelska.
Ingår i: Neurogastroenterology and Motility. - : Wiley. - 1350-1925 .- 1365-2982. ; 32:8
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background Aloe barbadensis Mill.(Aloe) with potential prebiotic effects has been suggested to reduce symptoms in patients with irritable bowel syndrome (IBS). We therefore aimed to determine the effects of an Aloe extract on symptoms of IBS, and evaluate whether effects may be mediated by fecal microbiota and metabolites in a randomized, double-blind, controlled trial. Methods Patient with IBS diagnosed according to the ROME III criteria (all subtypes), received Aloe or control treatment (inulin) for 4 weeks. IBS Symptom Severity Score (IBS-SSS) was assessed, and fecal samples collected before and at end of treatment. Fecal microbiota composition and metabolomic profile were determined. Key results In total, 160 IBS patients completed the study. The overall severity of IBS symptoms was reduced in both Aloe and control treatment groups (P < .001, both groups, comparing baseline vs end of treatment), without difference between groups (P = .62). The frequency of responders (IBS-SSS reduction >= 50) did not differ between Aloe treatment (n = 33, 39%) and control (n = 34, 45%) (P = .49). However, fecal microbiota and metabolite profiles differed between Aloe, but not control treatment responders and non-responders both before and after treatment. Conclusion In a mixed group of IBS patients, Aloe was not superior to control treatment, although it showed potential to reduce IBS symptom severity in subsets of IBS patients which could be predicted by fecal microbiota and metabolite profiles. ClinicalTrials.gov no: NCT01400048.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Neurosciences (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Gastroenterologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)

Nyckelord

Aloe
fecal metabolites
gastrointestinal microbiota
gastrointestinal
symptoms
irritable bowel syndrome
prebiotic
placebo-controlled trial
double-blind
alternative medicine
vera gel
complementary
inulin
avh200(r)
system
Gastroenterology & Hepatology
Neurosciences & Neurology
gastrointestinal symptoms

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy